RNA sequencing is emerging as a powerful technique to detect a diverse array of fusions in 36 human neoplasia, but few clinically validated assays have been described to date. We designed 37 and validated a hybrid-capture RNAseq assay for FFPE tissue (Fusion-STAMP). It fully targets 38 the transcript isoforms of 43 genes selected for their known impact as actionable targets of 39 existing and emerging anti-cancer therapies (especially in lung adenocarcinomas), prognostic 40 features, and/or utility as diagnostic cancer biomarkers (especially in sarcomas). 57 fusion results 41 across 34 samples were evaluated. Fusion-STAMP demonstrated high overall accuracy with 98% 42 sensitivity and 94% specificity for fusion detection. There was high intra-and inter-run 43 reproducibility. Detection was sensitive to approximately 10% tumor, though this is expected to 44 be impacted by fusion transcript expression levels, hybrid capture efficiency, and RNA quality. 45
Introduction: 58
In human neoplasia, numerous clinically relevant translocations have been described, and 59 more continue to be identified. Many are specific to one or several diagnoses, especially among 60 soft tissue neoplasms .  In  conjunction  with  clinical  history  and  61 histomorphologic/immunohistochemical findings, the detection of one of these translocations is a 62 valuable diagnostic adjunct 1 . For example, in the setting of a small round blue cell tumor, 63 translocation testing can help distinguish among differential diagnoses that include Ewing 64 sarcoma, Ewing-like sarcomas, desmoplastic small round cell tumor, alveolar 65 rhabdomyosarcoma, and synovial sarcoma, all of which are associated with distinct 66 translocations or sets of translocations. 67
Other translocations may guide therapeutic decision making to optimally utilize targeted 68 therapies, particularly in the setting of non-small cell lung carcinoma (NSCLC) 2 . For example, 69 ALK, ROS1, and RET rearrangements are standard-of-care biomarkers predictive of a response 70 to an FDA-approved medication in the setting of NSCLC. In addition, evidence is accumulating 71 for clinical actionability of many other structural rearrangements in NSCLC and other tumors [3] [4] [5] . 72 Numerous techniques have been employed to detect fusions 3 . Traditional methods that do 73 not employ next generation sequencing (NGS) include karyotyping, reverse transcriptase 74 polymerase chain reaction (RT-PCR), and fluorescent in situ hybridization (FISH) . Each of these 75 methods has specific strengths and limitations. Karyotyping relies on growing cells in culture, 76 can only detect large-scale alterations, demands significant interpretation time and can suffer 77 from long turnaround time. RT-PCR is a sensitive and specific technique to test for well-78 characterized fusions with stereotyped breakpoints, but suffers from a limited ability to 79 multiplex, or to detect novel rearrangements. FISH is considered the current gold standard for 80 detecting fusions; though it greatly improves resolution compared to karyotyping, it still suffers 81 from reduced sensitivity compared to NGS-based methods 6 , especially for small 82 intrachromosomal events ("cryptic rearrangements"). Furthermore, FISH is unable to determine 83 more granular details pertaining to fusions, including the fusion breakpoints, involved exons, and 84 whether the fusion is in-frame or not. There is emerging evidence that these parameters may be 85 clinically relevant. For example, in one reported cohort of patients with NSCLC positive by 86 FISH testing for an EML4-ALK rearrangement and treated with ALK inhibitors, upon DNA and 87 RNA NGS sequencing, patients with a predicted non-productive or no NGS-detectable EML4-88 ALK fusion demonstrated significantly worse mean survival compared to those with a predicted 89 productive rearrangement 7 . 90
In more recent years, NGS-based fusion detection techniques have been developed. 91
These include genomic DNA sequencing with target enrichment for regions in which breakpoints 92 occur (such as selected "hotspot" introns) 8, 9 , whole-transcriptome RNA sequencing utilizing 93 poly(A) capture 10 , and targeted RNA sequencing employing hybridization-based capture 11, 12 or 94 anchored multiplex PCR 13 . Broadly speaking, NGS-based techniques offer the advantage of 95 greater breadth, depth, and resolution compared to traditional methods, with a tradeoff of 96 increased cost. 97
Fresh tissue offers the best biospecimen quality characteristics for most molecular assays, 98 but suffers from a lack of convenience, availability, and portability. In both clinical and research 99 settings, formalin-fixed paraffin-embedded (FFPE) tissue has key advantages. These include 100 being generated routinely in the clinical workflow and being a stable source of DNA and/or 101 RNA for years after the tissue is acquired from the patient. In clinical practice, the need for 102 fusion detection may not become apparent until after specimens are fixed and sections are 103 examined under the microscope by a pathologist; also, the clinical need for fusion detection may 104 change over time due to changes in the patient's disease status, or evolution of knowledge in the 105 field. However, FFPE presents significant biospecimen quality challenges to molecular assays 106 due to chemical modifications including cross-linking which occur to DNA and RNA during 107 fixation 14, 15 . Cross-linking results in fragmentation, which limits the quantity of intact nucleic 108 acids available for testing, and the obtainable length of NGS sequencing reads. 109
Each NGS-based fusion detection technique has advantages and limitations. Targeted 110 DNA panels commonly used in cancer profiling can conveniently incorporate fusion detection by 111 covering "hotspot" breakpoint regions and detecting fusion "spanning" or fusion "straddling" 112 reads 8, 9 . However, these panels can only capture a fraction of possible breakpoints, limited by 113 intron sizes and fusion breakpoint diversity. Furthermore, targeted DNA panels on FFPE 114 specimens have difficulties with repetitive or low complexity regions due to short read lengths; 115 unfortunately, such regions often mediate genomic rearrangements 16 . On the other hand, RNA-116 based methods cannot detect rearrangements that do not lead to a fusion transcript, such as those 117 that upregulate a gene's expression by juxtaposing an enhancer element (eg, rearrangements 118 involving IGH in some types of lymphoma), and may also miss lowly-expressed fusion 119 transcripts. However, RNA-based NGS techniques can efficiently detect a diverse range of 120 fusion breakpoints. Whole-transcriptome RNA sequencing using poly(A) capture on FFPE 121 specimens for fusion detection has recently been reported 10 . This approach offers a wide breadth 122 of sequencing and correspondingly a high discovery potential for novel fusions, which may be 123 especially valuable in a research setting. However, due to RNA fragmentation, sensitivity 124 decreases with the distance of the breakpoint from the poly(A) tail (ie breakpoints that are more 125 5' in the fusion transcript suffer from reduced sensitivity) 10 The Fusion STAMP workflow includes isolation of total RNA molecules, followed by 219 efficient preparation of sequencing libraries and a target enrichment approach to capture mRNA 220 transcript regions of interest for sequencing. The enrichment is done using custom designed 221 libraries of capture oligonucleotides that target a specific set of expressed genomic regions. This 222 panel fully targets the major canonical transcript isoforms of the 43 genes described above. The 223 bioinformatic pipeline includes sequencing quality control, paired-end mapping to the human 224 transcriptome, and detection of gene fusion events using the STAR-Fusion algorithm. In 225 addition, quality control metrics and plots are generated from the aligned BAM files. A 226 molecular genetic pathology fellow or clinical molecular genetics fellow reviews all fusion 227 variant calls. 228
229

Sequencing Metrics and Clinical Reporting Thresholds 230
Sequencing metrics across the 34 tested samples (Table 2) Fusion STAMP showed excellent accuracy (Table 3) . One case was negative by FISH for 278 USP6 but Fusion STAMP was positive for a COL1A1-USP6 fusion. Given the tumor context (a 279 fibro-osseous pseudotumor of the digit), this likely represents a false negative result by FISH 280 testing. Fusion-STAMP is expected to show greater analytical sensitivity than FISH. 281
One case was positive by outside testing for an EML4-ALK rearrangement, but this was 282 not detected by Fusion STAMP. In this case, the outside lab performed micro-dissection for 283 tumor enrichment. This was not an option with the material received for Fusion STAMP; this 284 may account for this false negative result. 285
Of the 43 genes in this panel, 27 are involved in at least one fusion in the validation data 286 set. Of the remaining 16 genes, many are rarely involved in fusions, making it a challenge to 287 obtain reference material. To demonstrate that the selector was successful in capturing these 288 transcripts when expressed, we examined the coverage data in appropriate tissue types among 289 our validation samples. Demonstrable capture was identified for all transcripts on the selector in 290 at least one sample. 291 292
Discussion: 293
Though RNAseq on FFPE promises multiple advantages over DNA sequencing, it also 294 comes with numerous challenges. This includes a low average RNA quality in FFPE specimens, 295 and variable RNA total content and expression profile per cell. The downstream effects of these 296 issues can be seen in highly variable on-target rates, total read pairs, and total mapped read pairs 297 in the Fusion STAMP validation cohort. Tumor percentage estimates, while still important, are 298 less directly related to the fraction of RNA read pairs that originate from the tumor than they 299 would be for DNA. It is conceivable that a lowly expressed fusion could be missed despite 300 relatively high tumor percentage, especially in a poor-quality specimen. Also, given the 301 multiplex design, even though the hybrid capture input RNA mass per sample is constant, 302 variable expression profiles between samples can result in disproportionate sequencing of some 303 samples with greater RNA content aligning to the selector at the expense of other samples. 304
The sensitivity of Fusion STAMP is estimated to be around 10% tumor based on the 305 EWSR1 cell line dilution study performed during validation; however, this sensitivity is 306 expected to vary significantly by the hybrid capture efficiency of the involved genes, the fusion 307 transcript expression level, and the specimen quality. One false negative was identified in the 308 validation cohort and appears likely to relate to low tumor percent due to lack of enrichment, and 309 poor RNA quality. However, Fusion STAMP demonstrated high sensitivity for fusion detection 310
overall. 311
False positive results may be caused by intergenic splicing 21 , barcode hopping / index 312 hopping 22 , or misalignment. These findings are expected to vary depending on the expression 313 profile of the sample, and therefore will likely vary by the site of origin of the tissue. The full 314 range of human tissue types is near-impossible to comprehensively assess during validation. 315
Several tissue types were tested during validation including lung, gastrointestinal tract, and soft 316 tissue, and no false positives were detected above the reporting thresholds. As clinical testing 317 continues and more tissue types are sequenced, recurrent artifacts will be prospectively tracked, 318 identified, and/or filtered. 319
Multiple RNA NGS sequencing quality control strategies and metrics have been 320 described in the literature. These include spike-in control transcripts and corresponding probes to 321 assess efficiency of hybrid capture and indirectly assess RNA quality 11 ; probes to RNA from 322 housekeeping genes to assess RNA quality 11 ; a minimum total mapped read count 10, 11, 13 ; a 323 minimum on-target rate 11 ; a minimum mapped exon-exon junction read count 10 ; a percent of 324 mapped reads that map to coding regions 10 ; and qPCR-based assessment of RNA quality 13 . The 325 utility of these metrics needs to be weighed against the theoretical possibility of detecting a 326 highly expressed fusion despite poor quality, or of missing a lowly expressed fusion despite high 327 quality. This makes it challenging to have an accurate assessment of the risk of a false positive or 328 negative result in any individual case. For this Fusion STAMP validation cohort, despite 329 employing only run-level QC criteria and sample-specific total mapped reads QC cutoffs, after 330 optimizing reporting cutoffs to exclude noise and include real events as confirmed by ancillary 331 testing, the cohort demonstrates a high sensitivity, specificity, precision and accuracy for 332 qualitative fusion detection. 
